Share Price and Basic Stock Data
Last Updated: December 16, 2025, 10:50 pm
| PEG Ratio | -11.48 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Chandra Bhagat Pharma Ltd operates within the pharmaceuticals sector, currently priced at ₹45.00 with a market capitalization of ₹34.00 Cr. The company has shown fluctuating revenue trends over recent periods. For instance, sales rose from ₹22.36 Cr in September 2020 to ₹119.26 Cr by September 2023, demonstrating a significant growth trajectory. However, sales are projected to decline to ₹21.80 Cr by March 2025, indicating potential volatility in revenue streams. The latest annual sales for FY 2023 stood at ₹119.67 Cr, with a notable increase expected in FY 2024 to ₹221.37 Cr, before reverting to ₹86.72 Cr in FY 2025. This inconsistency in revenue highlights both growth potential and risk, as the company must navigate market challenges to sustain performance. The operating profit margin (OPM) has remained negative recently, particularly at -4.19% in September 2023, reflecting operational challenges despite higher sales figures. Overall, the revenue trends indicate a company that has experienced growth but faces significant hurdles in maintaining profitability.
Profitability and Efficiency Metrics
Chandra Bhagat Pharma’s profitability metrics reveal a challenging financial landscape. The company reported a net profit of ₹0.62 Cr for the latest quarter, with a net profit margin of 0.98% for FY 2025. While the net profit increased from ₹0.03 Cr in September 2020 to ₹0.63 Cr in September 2023, the profitability ratios, such as return on equity (ROE) at 2.41% and return on capital employed (ROCE) at 6.00%, indicate inefficiencies compared to industry averages. The interest coverage ratio (ICR) of 2.09x suggests the company can cover its interest expenses, but the declining trend in operating profit from ₹1.80 Cr in March 2023 to -₹2.04 Cr by March 2024 raises concerns. Additionally, the cash conversion cycle stands at 110.17 days, signaling potential inefficiencies in managing receivables and inventory. These profitability and efficiency metrics highlight a firm that is struggling to convert sales into sustainable profit, necessitating operational improvements to enhance overall financial health.
Balance Sheet Strength and Financial Ratios
The balance sheet of Chandra Bhagat Pharma reflects a mixed picture of financial health. As of March 2025, the company reported total borrowings of ₹21.11 Cr against reserves of ₹22.87 Cr, indicating a tight leverage position. The debt-to-equity ratio stands at 0.69x, suggesting a moderate reliance on debt financing. The current ratio of 1.41x indicates adequate short-term liquidity, while the quick ratio of 1.40x confirms that the company can meet its short-term obligations without relying on inventory sales. However, the book value per share increased to ₹39.72, providing a sense of stability in terms of shareholder equity. The efficiency ratios, including an asset turnover ratio of 0.85%, reveal that the company generates a lower return on its assets compared to its peers. This combination of moderate leverage and liquidity positions the firm reasonably well, yet highlights the need for improved operational effectiveness and asset utilization to enhance shareholder value in the long term.
Shareholding Pattern and Investor Confidence
Chandra Bhagat Pharma’s shareholding pattern reflects a strong promoter presence, with promoters holding 72.19% of the total equity. This substantial ownership can instill confidence among investors, as it suggests commitment from the founding members. However, foreign institutional investors (FIIs) hold only 0.61%, and domestic institutional investors (DIIs) have no significant stake, which may limit broader market confidence. The number of shareholders has decreased to 301, down from a peak of 316, indicating a potential decline in retail interest. The public shareholding currently stands at 27.20%, which is relatively low and could suggest a lack of diversification among investors. This concentrated ownership may pose risks if the promoters decide to divest or if operational challenges persist. Overall, while the high promoter stake is a positive aspect, the low institutional ownership and declining retail interest may raise red flags regarding investor confidence and market perception.
Outlook, Risks, and Final Insight
The outlook for Chandra Bhagat Pharma appears mixed, with both opportunities for growth and significant risks ahead. The company has the potential to capitalize on its recent sales increases, particularly with FY 2024 projected sales reaching ₹221.37 Cr. However, the anticipated decline in revenue to ₹86.72 Cr in FY 2025 poses a substantial risk to financial stability. Major challenges include the persistent negative operating profit margins and low ROE and ROCE figures, which signal inefficiencies in converting sales into profits. Additionally, the reliance on promoter holdings and lack of institutional interest may limit external support for future growth initiatives. The company must address operational inefficiencies and enhance profitability to regain investor confidence. In summary, while Chandra Bhagat Pharma has demonstrated growth potential, it must navigate significant operational and market risks to achieve sustainable success in the competitive pharmaceutical sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 99.8 | 231/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,816 Cr. | 443 | 479/192 | 99.7 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.3 Cr. | 49.0 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 50.6 Cr. | 34.6 | 35.0/17.0 | 120 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,100.18 Cr | 1,149.90 | 52.73 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22.36 | 48.33 | 43.15 | 50.93 | 44.27 | 75.40 | 119.26 | 102.11 | 64.92 | 21.80 |
| Expenses | 20.71 | 46.67 | 41.53 | 49.87 | 43.24 | 73.60 | 124.26 | 104.15 | 66.11 | 22.06 |
| Operating Profit | 1.65 | 1.66 | 1.62 | 1.06 | 1.03 | 1.80 | -5.00 | -2.04 | -1.19 | -0.26 |
| OPM % | 7.38% | 3.43% | 3.75% | 2.08% | 2.33% | 2.39% | -4.19% | -2.00% | -1.83% | -1.19% |
| Other Income | 0.02 | 0.46 | 0.47 | 1.15 | 0.60 | 0.19 | 7.01 | 4.32 | 3.07 | 2.45 |
| Interest | 1.62 | 1.86 | 1.45 | 1.63 | 1.04 | 1.15 | 0.66 | 0.73 | 0.85 | 1.10 |
| Depreciation | 0.01 | 0.02 | 0.06 | 0.06 | 0.05 | 0.22 | 0.43 | 0.21 | 0.41 | 0.54 |
| Profit before tax | 0.04 | 0.24 | 0.58 | 0.52 | 0.54 | 0.62 | 0.92 | 1.34 | 0.62 | 0.55 |
| Tax % | 25.00% | 33.33% | 24.14% | 30.77% | 31.48% | 14.52% | 31.52% | 33.58% | -11.29% | 69.09% |
| Net Profit | 0.03 | 0.16 | 0.43 | 0.36 | 0.37 | 0.54 | 0.63 | 0.90 | 0.68 | 0.17 |
| EPS in Rs | 0.04 | 0.21 | 0.57 | 0.48 | 0.49 | 0.72 | 0.83 | 1.19 | 0.90 | 0.23 |
Last Updated: May 31, 2025, 6:33 am
Below is a detailed analysis of the quarterly data for Chandra Bhagat Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 21.80 Cr.. The value appears to be declining and may need further review. It has decreased from 64.92 Cr. (Sep 2024) to 21.80 Cr., marking a decrease of 43.12 Cr..
- For Expenses, as of Mar 2025, the value is 22.06 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 66.11 Cr. (Sep 2024) to 22.06 Cr., marking a decrease of 44.05 Cr..
- For Operating Profit, as of Mar 2025, the value is -0.26 Cr.. The value appears strong and on an upward trend. It has increased from -1.19 Cr. (Sep 2024) to -0.26 Cr., marking an increase of 0.93 Cr..
- For OPM %, as of Mar 2025, the value is -1.19%. The value appears strong and on an upward trend. It has increased from -1.83% (Sep 2024) to -1.19%, marking an increase of 0.64%.
- For Other Income, as of Mar 2025, the value is 2.45 Cr.. The value appears to be declining and may need further review. It has decreased from 3.07 Cr. (Sep 2024) to 2.45 Cr., marking a decrease of 0.62 Cr..
- For Interest, as of Mar 2025, the value is 1.10 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.85 Cr. (Sep 2024) to 1.10 Cr., marking an increase of 0.25 Cr..
- For Depreciation, as of Mar 2025, the value is 0.54 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.41 Cr. (Sep 2024) to 0.54 Cr., marking an increase of 0.13 Cr..
- For Profit before tax, as of Mar 2025, the value is 0.55 Cr.. The value appears to be declining and may need further review. It has decreased from 0.62 Cr. (Sep 2024) to 0.55 Cr., marking a decrease of 0.07 Cr..
- For Tax %, as of Mar 2025, the value is 69.09%. The value appears to be increasing, which may not be favorable. It has increased from -11.29% (Sep 2024) to 69.09%, marking an increase of 80.38%.
- For Net Profit, as of Mar 2025, the value is 0.17 Cr.. The value appears to be declining and may need further review. It has decreased from 0.68 Cr. (Sep 2024) to 0.17 Cr., marking a decrease of 0.51 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.23. The value appears to be declining and may need further review. It has decreased from 0.90 (Sep 2024) to 0.23, marking a decrease of 0.67.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:59 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 48.01 | 61.13 | 79.84 | 89.79 | 97.06 | 106.28 | 93.97 | 70.70 | 94.04 | 119.67 | 221.37 | 86.72 | 47.35 |
| Expenses | 46.18 | 58.13 | 76.42 | 85.41 | 92.47 | 101.69 | 90.85 | 67.02 | 91.20 | 116.33 | 228.41 | 88.14 | 45.94 |
| Operating Profit | 1.83 | 3.00 | 3.42 | 4.38 | 4.59 | 4.59 | 3.12 | 3.68 | 2.84 | 3.34 | -7.04 | -1.42 | 1.41 |
| OPM % | 3.81% | 4.91% | 4.28% | 4.88% | 4.73% | 4.32% | 3.32% | 5.21% | 3.02% | 2.79% | -3.18% | -1.64% | 2.98% |
| Other Income | 0.64 | 0.31 | 0.38 | 0.49 | 0.67 | 0.44 | 0.44 | 0.48 | 1.62 | 0.29 | 11.33 | 5.49 | 2.79 |
| Interest | 1.88 | 2.35 | 2.83 | 3.81 | 3.67 | 4.09 | 3.11 | 3.76 | 3.24 | 2.20 | 1.39 | 1.95 | 1.91 |
| Depreciation | 0.17 | 0.26 | 0.24 | 0.14 | 0.06 | 0.05 | 0.03 | 0.12 | 0.12 | 0.27 | 0.64 | 0.95 | 1.15 |
| Profit before tax | 0.42 | 0.70 | 0.73 | 0.92 | 1.53 | 0.89 | 0.42 | 0.28 | 1.10 | 1.16 | 2.26 | 1.17 | 1.14 |
| Tax % | 16.67% | 38.57% | 50.68% | 27.17% | 32.68% | 22.47% | 26.19% | 32.14% | 27.27% | 21.55% | 32.74% | 26.50% | |
| Net Profit | 0.35 | 0.43 | 0.35 | 0.66 | 1.03 | 0.69 | 0.31 | 0.19 | 0.80 | 0.91 | 1.53 | 0.86 | 0.62 |
| EPS in Rs | 8.37 | 10.29 | 8.37 | 15.79 | 24.64 | 10.29 | 0.41 | 0.25 | 1.06 | 1.21 | 2.03 | 1.14 | 0.83 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 22.86% | -18.60% | 88.57% | 56.06% | -33.01% | -55.07% | -38.71% | 321.05% | 13.75% | 68.13% | -43.79% |
| Change in YoY Net Profit Growth (%) | 0.00% | -41.46% | 107.18% | -32.51% | -89.07% | -22.06% | 16.36% | 359.76% | -307.30% | 54.38% | -111.92% |
Chandra Bhagat Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | -2% |
| 3 Years: | -3% |
| TTM: | -61% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 23% |
| 3 Years: | 2% |
| TTM: | -44% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 4% |
| 3 Years: | -23% |
| 1 Year: | -39% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 3% |
| 3 Years: | 4% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 2:51 pm
Balance Sheet
Last Updated: December 4, 2025, 2:36 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.42 | 0.42 | 0.42 | 0.42 | 0.42 | 0.67 | 7.55 | 7.55 | 7.55 | 7.55 | 7.55 | 7.55 | 7.55 |
| Reserves | 5.55 | 5.98 | 6.33 | 6.99 | 8.03 | 13.78 | 18.14 | 18.33 | 19.13 | 19.93 | 21.46 | 22.42 | 22.87 |
| Borrowings | 18.58 | 27.50 | 27.83 | 22.08 | 21.75 | 31.22 | 29.93 | 27.07 | 21.11 | 18.94 | 16.43 | 20.86 | 21.11 |
| Other Liabilities | 7.07 | 8.39 | 9.91 | 26.40 | 27.86 | 37.19 | 19.12 | 18.83 | 24.68 | 14.16 | 56.37 | 50.70 | 36.67 |
| Total Liabilities | 31.62 | 42.29 | 44.49 | 55.89 | 58.06 | 82.86 | 74.74 | 71.78 | 72.47 | 60.58 | 101.81 | 101.53 | 88.20 |
| Fixed Assets | 1.02 | 0.87 | 0.69 | 0.55 | 0.51 | 0.46 | 0.44 | 0.42 | 0.47 | 0.73 | 2.52 | 2.62 | 2.04 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 4.64 | 1.05 | 4.03 | 0.75 | 0.00 | 0.22 | 0.11 | 0.13 | 0.14 | 1.19 |
| Other Assets | 30.60 | 41.42 | 43.80 | 50.70 | 56.50 | 78.37 | 73.55 | 71.36 | 71.78 | 59.74 | 99.16 | 98.77 | 84.97 |
| Total Assets | 31.62 | 42.29 | 44.49 | 55.89 | 58.06 | 82.86 | 74.74 | 71.78 | 72.47 | 60.58 | 101.81 | 101.53 | 88.20 |
Below is a detailed analysis of the balance sheet data for Chandra Bhagat Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 7.55 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 7.55 Cr..
- For Reserves, as of Sep 2025, the value is 22.87 Cr.. The value appears strong and on an upward trend. It has increased from 22.42 Cr. (Mar 2025) to 22.87 Cr., marking an increase of 0.45 Cr..
- For Borrowings, as of Sep 2025, the value is 21.11 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 20.86 Cr. (Mar 2025) to 21.11 Cr., marking an increase of 0.25 Cr..
- For Other Liabilities, as of Sep 2025, the value is 36.67 Cr.. The value appears to be improving (decreasing). It has decreased from 50.70 Cr. (Mar 2025) to 36.67 Cr., marking a decrease of 14.03 Cr..
- For Total Liabilities, as of Sep 2025, the value is 88.20 Cr.. The value appears to be improving (decreasing). It has decreased from 101.53 Cr. (Mar 2025) to 88.20 Cr., marking a decrease of 13.33 Cr..
- For Fixed Assets, as of Sep 2025, the value is 2.04 Cr.. The value appears to be declining and may need further review. It has decreased from 2.62 Cr. (Mar 2025) to 2.04 Cr., marking a decrease of 0.58 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 1.19 Cr.. The value appears strong and on an upward trend. It has increased from 0.14 Cr. (Mar 2025) to 1.19 Cr., marking an increase of 1.05 Cr..
- For Other Assets, as of Sep 2025, the value is 84.97 Cr.. The value appears to be declining and may need further review. It has decreased from 98.77 Cr. (Mar 2025) to 84.97 Cr., marking a decrease of 13.80 Cr..
- For Total Assets, as of Sep 2025, the value is 88.20 Cr.. The value appears to be declining and may need further review. It has decreased from 101.53 Cr. (Mar 2025) to 88.20 Cr., marking a decrease of 13.33 Cr..
Notably, the Reserves (22.87 Cr.) exceed the Borrowings (21.11 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -16.75 | -24.50 | -24.41 | -17.70 | -17.16 | -26.63 | -26.81 | -23.39 | -18.27 | -15.60 | -23.47 | -22.28 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 65.15 | 70.99 | 66.15 | 79.92 | 67.16 | 90.32 | 54.50 | 79.61 | 58.22 | 24.98 | 65.05 | 151.31 |
| Inventory Days | 161.44 | 176.71 | 122.83 | 132.66 | 144.60 | 173.53 | 186.75 | 214.70 | 153.25 | 99.59 | 15.23 | 3.44 |
| Days Payable | 53.01 | 43.18 | 32.81 | 80.69 | 68.58 | 117.37 | 53.13 | 78.51 | 11.98 | 10.62 | 23.21 | 44.58 |
| Cash Conversion Cycle | 173.59 | 204.52 | 156.17 | 131.89 | 143.18 | 146.48 | 188.12 | 215.80 | 199.49 | 113.95 | 57.06 | 110.17 |
| Working Capital Days | 148.78 | 166.47 | 133.63 | 124.96 | 138.50 | 83.39 | 147.60 | 177.18 | 103.94 | 75.00 | 35.89 | 115.28 |
| ROCE % | 11.68% | 10.44% | 10.40% | 14.77% | 17.42% | 13.13% | 6.97% | 7.44% | 8.62% | 7.13% | 7.95% | 6.00% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.14 | 2.03 | 1.20 | 1.06 | 0.25 |
| Diluted EPS (Rs.) | 1.14 | 2.03 | 1.20 | 1.06 | 0.25 |
| Cash EPS (Rs.) | 2.40 | 2.88 | 1.55 | 1.22 | 0.29 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 39.72 | 38.45 | 36.42 | 35.35 | 34.30 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 39.72 | 38.45 | 36.42 | 35.35 | 34.30 |
| Revenue From Operations / Share (Rs.) | 114.93 | 293.40 | 158.61 | 124.68 | 93.70 |
| PBDIT / Share (Rs.) | 5.39 | 5.69 | 4.79 | 5.69 | 1.05 |
| PBIT / Share (Rs.) | 4.13 | 4.84 | 4.44 | 5.53 | 1.01 |
| PBT / Share (Rs.) | 1.54 | 3.00 | 1.54 | 1.45 | 0.36 |
| Net Profit / Share (Rs.) | 1.14 | 2.03 | 1.20 | 1.05 | 0.25 |
| PBDIT Margin (%) | 4.68 | 1.93 | 3.01 | 4.56 | 1.12 |
| PBIT Margin (%) | 3.58 | 1.64 | 2.79 | 4.43 | 1.07 |
| PBT Margin (%) | 1.34 | 1.02 | 0.97 | 1.16 | 0.39 |
| Net Profit Margin (%) | 0.98 | 0.69 | 0.75 | 0.84 | 0.26 |
| Return on Networth / Equity (%) | 2.86 | 5.27 | 3.29 | 2.98 | 0.73 |
| Return on Capital Employeed (%) | 9.64 | 11.86 | 9.95 | 12.12 | 1.95 |
| Return On Assets (%) | 0.84 | 1.50 | 1.49 | 1.09 | 0.26 |
| Long Term Debt / Equity (X) | 0.07 | 0.04 | 0.14 | 0.20 | 0.36 |
| Total Debt / Equity (X) | 0.69 | 0.56 | 0.68 | 0.74 | 0.96 |
| Asset Turnover Ratio (%) | 0.85 | 2.73 | 1.80 | 1.30 | 0.96 |
| Current Ratio (X) | 1.41 | 1.38 | 2.19 | 1.86 | 2.13 |
| Quick Ratio (X) | 1.40 | 1.26 | 1.11 | 0.96 | 1.06 |
| Inventory Turnover Ratio (X) | 18.51 | 1.54 | 0.53 | 0.07 | 0.23 |
| Interest Coverage Ratio (X) | 2.09 | 3.09 | 1.65 | 1.40 | 1.65 |
| Interest Coverage Ratio (Post Tax) (X) | 1.44 | 2.10 | 1.41 | 1.26 | 1.39 |
| Enterprise Value (Cr.) | 59.68 | 83.14 | 85.69 | 99.92 | 52.54 |
| EV / Net Operating Revenue (X) | 0.68 | 0.37 | 0.71 | 1.06 | 0.74 |
| EV / EBITDA (X) | 14.68 | 19.38 | 23.71 | 23.26 | 66.02 |
| MarketCap / Net Operating Revenue (X) | 0.45 | 0.32 | 0.61 | 0.91 | 0.42 |
| Price / BV (X) | 1.32 | 2.47 | 2.66 | 3.22 | 1.15 |
| Price / Net Operating Revenue (X) | 0.45 | 0.32 | 0.61 | 0.91 | 0.42 |
| EarningsYield | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Chandra Bhagat Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 5. It has decreased from 2.03 (Mar 24) to 1.14, marking a decrease of 0.89.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 5. It has decreased from 2.03 (Mar 24) to 1.14, marking a decrease of 0.89.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.40. This value is below the healthy minimum of 3. It has decreased from 2.88 (Mar 24) to 2.40, marking a decrease of 0.48.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 39.72. It has increased from 38.45 (Mar 24) to 39.72, marking an increase of 1.27.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 39.72. It has increased from 38.45 (Mar 24) to 39.72, marking an increase of 1.27.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 114.93. It has decreased from 293.40 (Mar 24) to 114.93, marking a decrease of 178.47.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 5.39. This value is within the healthy range. It has decreased from 5.69 (Mar 24) to 5.39, marking a decrease of 0.30.
- For PBIT / Share (Rs.), as of Mar 25, the value is 4.13. This value is within the healthy range. It has decreased from 4.84 (Mar 24) to 4.13, marking a decrease of 0.71.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.54. This value is within the healthy range. It has decreased from 3.00 (Mar 24) to 1.54, marking a decrease of 1.46.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 2. It has decreased from 2.03 (Mar 24) to 1.14, marking a decrease of 0.89.
- For PBDIT Margin (%), as of Mar 25, the value is 4.68. This value is below the healthy minimum of 10. It has increased from 1.93 (Mar 24) to 4.68, marking an increase of 2.75.
- For PBIT Margin (%), as of Mar 25, the value is 3.58. This value is below the healthy minimum of 10. It has increased from 1.64 (Mar 24) to 3.58, marking an increase of 1.94.
- For PBT Margin (%), as of Mar 25, the value is 1.34. This value is below the healthy minimum of 10. It has increased from 1.02 (Mar 24) to 1.34, marking an increase of 0.32.
- For Net Profit Margin (%), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 5. It has increased from 0.69 (Mar 24) to 0.98, marking an increase of 0.29.
- For Return on Networth / Equity (%), as of Mar 25, the value is 2.86. This value is below the healthy minimum of 15. It has decreased from 5.27 (Mar 24) to 2.86, marking a decrease of 2.41.
- For Return on Capital Employeed (%), as of Mar 25, the value is 9.64. This value is below the healthy minimum of 10. It has decreased from 11.86 (Mar 24) to 9.64, marking a decrease of 2.22.
- For Return On Assets (%), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 5. It has decreased from 1.50 (Mar 24) to 0.84, marking a decrease of 0.66.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 0.2. It has increased from 0.04 (Mar 24) to 0.07, marking an increase of 0.03.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.69. This value is within the healthy range. It has increased from 0.56 (Mar 24) to 0.69, marking an increase of 0.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.85. It has decreased from 2.73 (Mar 24) to 0.85, marking a decrease of 1.88.
- For Current Ratio (X), as of Mar 25, the value is 1.41. This value is below the healthy minimum of 1.5. It has increased from 1.38 (Mar 24) to 1.41, marking an increase of 0.03.
- For Quick Ratio (X), as of Mar 25, the value is 1.40. This value is within the healthy range. It has increased from 1.26 (Mar 24) to 1.40, marking an increase of 0.14.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 18.51. This value exceeds the healthy maximum of 8. It has increased from 1.54 (Mar 24) to 18.51, marking an increase of 16.97.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.09. This value is below the healthy minimum of 3. It has decreased from 3.09 (Mar 24) to 2.09, marking a decrease of 1.00.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.44. This value is below the healthy minimum of 3. It has decreased from 2.10 (Mar 24) to 1.44, marking a decrease of 0.66.
- For Enterprise Value (Cr.), as of Mar 25, the value is 59.68. It has decreased from 83.14 (Mar 24) to 59.68, marking a decrease of 23.46.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1. It has increased from 0.37 (Mar 24) to 0.68, marking an increase of 0.31.
- For EV / EBITDA (X), as of Mar 25, the value is 14.68. This value is within the healthy range. It has decreased from 19.38 (Mar 24) to 14.68, marking a decrease of 4.70.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.45. This value is below the healthy minimum of 1. It has increased from 0.32 (Mar 24) to 0.45, marking an increase of 0.13.
- For Price / BV (X), as of Mar 25, the value is 1.32. This value is within the healthy range. It has decreased from 2.47 (Mar 24) to 1.32, marking a decrease of 1.15.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.45. This value is below the healthy minimum of 1. It has increased from 0.32 (Mar 24) to 0.45, marking an increase of 0.13.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Chandra Bhagat Pharma Ltd:
- Net Profit Margin: 0.98%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 9.64% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 2.86% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.44
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.4
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 54.8 (Industry average Stock P/E: 52.73)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.69
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.98%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 323-F Bhagat Bhuvan, Dr. Ambedkar Road, Mumbai Maharashtra 400019 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Hemant Chandravadan Bhagat | Chairman & Managing Director |
| Mr. Pranav Hemant Bhagat | Whole Time Director |
| Ms. Prachi Pranav Bhagat | Director & CFO |
| Mr. Ravindra Gajanan Awati | Independent Director |
| Ms. Abha Praveen Doshi | Independent Director |
FAQ
What is the intrinsic value of Chandra Bhagat Pharma Ltd?
Chandra Bhagat Pharma Ltd's intrinsic value (as of 26 December 2025) is 43.43 which is 3.49% lower the current market price of 45.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 34.0 Cr. market cap, FY2025-2026 high/low of 80.0/33.0, reserves of ₹22.87 Cr, and liabilities of 88.20 Cr.
What is the Market Cap of Chandra Bhagat Pharma Ltd?
The Market Cap of Chandra Bhagat Pharma Ltd is 34.0 Cr..
What is the current Stock Price of Chandra Bhagat Pharma Ltd as on 26 December 2025?
The current stock price of Chandra Bhagat Pharma Ltd as on 26 December 2025 is 45.0.
What is the High / Low of Chandra Bhagat Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Chandra Bhagat Pharma Ltd stocks is 80.0/33.0.
What is the Stock P/E of Chandra Bhagat Pharma Ltd?
The Stock P/E of Chandra Bhagat Pharma Ltd is 54.8.
What is the Book Value of Chandra Bhagat Pharma Ltd?
The Book Value of Chandra Bhagat Pharma Ltd is 40.3.
What is the Dividend Yield of Chandra Bhagat Pharma Ltd?
The Dividend Yield of Chandra Bhagat Pharma Ltd is 0.00 %.
What is the ROCE of Chandra Bhagat Pharma Ltd?
The ROCE of Chandra Bhagat Pharma Ltd is 6.00 %.
What is the ROE of Chandra Bhagat Pharma Ltd?
The ROE of Chandra Bhagat Pharma Ltd is 2.41 %.
What is the Face Value of Chandra Bhagat Pharma Ltd?
The Face Value of Chandra Bhagat Pharma Ltd is 10.0.